Investigational Drug Information for Plinabulin
What is the development status for investigational drug Plinabulin?
Plinabulin is an investigational drug.
There have been 13 clinical trials for Plinabulin.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2026.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neutropenia. The leading clinical trial sponsors are BeyondSpring Pharmaceuticals Inc., Memorial Sloan Kettering Cancer Center, and Merck Sharp & Dohme LLC.
There are one hundred and thirty US patents protecting this investigational drug and two hundred and eighty-three international patents.
Summary for Plinabulin
| US Patents | 130 |
| International Patents | 283 |
| US Patent Applications | 290 |
| WIPO Patent Applications | 118 |
| Japanese Patent Applications | 26 |
| Clinical Trial Progress | Phase 3 (2026-06-01) |
| Vendors | 39 |
Recent Clinical Trials for Plinabulin
| Title | Sponsor | Phase |
|---|---|---|
| Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) | BeyondSpring Pharmaceuticals Inc. | PHASE3 |
| First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC | Xiaorong Dong | Phase 2 |
| Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | BeyondSpring Pharmaceuticals Inc. | Phase 2 |
Clinical Trial Summary for Plinabulin
Top disease conditions for Plinabulin
Top clinical trial sponsors for Plinabulin
US Patents for Plinabulin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Plinabulin | ⤷ Start Trial | Method of treating a brain tumor | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Start Trial |
| Plinabulin | ⤷ Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Start Trial |
| Plinabulin | ⤷ Start Trial | Nanoparticle formulations for delivering multiple therapeutic agents | AMRITA VISHWA VIDYAPEETHAM (Kochi, Kerala, unknown) | ⤷ Start Trial |
| Plinabulin | ⤷ Start Trial | Plinabulin compositions | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Start Trial |
| Plinabulin | ⤷ Start Trial | Method of treating cancer associated with a RAS mutation | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Start Trial |
| Plinabulin | ⤷ Start Trial | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | Duquesne University of the Holy Spirit (Pittsburgh, PA) | ⤷ Start Trial |
| Plinabulin | ⤷ Start Trial | Method of treating a brain tumor | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Plinabulin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Plinabulin | Australia | AU2016229295 | 2035-03-06 | ⤷ Start Trial |
| Plinabulin | Australia | AU2021254549 | 2035-03-06 | ⤷ Start Trial |
| Plinabulin | Brazil | BR112017018964 | 2035-03-06 | ⤷ Start Trial |
| Plinabulin | Canada | CA2978679 | 2035-03-06 | ⤷ Start Trial |
| Plinabulin | Chile | CL2017002242 | 2035-03-06 | ⤷ Start Trial |
| Plinabulin | China | CN107530340 | 2035-03-06 | ⤷ Start Trial |
| Plinabulin | European Patent Office | EP3265091 | 2035-03-06 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
